Group 1 - The core viewpoint of the news is that WuXi AppTec has announced a positive earnings forecast for FY2025, with significant revenue and profit growth, while also planning to acquire Dongyao Pharmaceutical to enhance its operational capacity in China [1] - WuXi AppTec expects a revenue growth of over 45% year-on-year for 2025, with gross profit increasing by more than 70% and adjusted net profit (excluding interest income and expenses) also rising over 45%, with a projected growth rate exceeding 65% after accounting for currency fluctuations [1] - The acquisition of Dongyao Pharmaceutical aims to expand WuXi AppTec's operational capacity and strengthen its overall capabilities, thereby enhancing its value-added services for biotech companies [1] Group 2 - The global ADC (Antibody-Drug Conjugate) market is projected to reach approximately $17.2 billion by 2025, with a compound annual growth rate (CAGR) of 30.6% from 2023 to 2032, and expected to exceed $115.1 billion by 2032 [1] - The ADC outsourcing services market is also experiencing strong growth, with an expected size of $11 billion by 2030 and a CAGR of 28.4% from 2022 to 2030, providing significant growth opportunities for CDMO companies [1] - WuXi AppTec has over 630 global cooperative clients and a total of 252 iCMC projects as of December 2025, along with 18 PPQ (Process Performance Qualification) projects and 1 commercial project [2]
业绩盈喜、控股收购东曜药业 药明合联进一步稳固ADC CDMO市场地位